Exact Sciences (EXAS)

Executive Summary

Exact Sciences is a leading molecular diagnostics company focused on cancer detection and treatment guidance, best known for its Cologuard stool DNA test for colorectal cancer screening. The company has established a dominant position in the $10B+ U.S. colorectal cancer screening market, with Cologuard being the only non-invasive, FDA-approved stool DNA test for average-risk adults aged 45 and older. In 2024, Exact Sciences launched Cologuard 2.0, a next-generation version with improved sensitivity and specificity, which is expected to drive market share gains and reimbursement expansion. The company generates over $2B in annual revenue and continues to invest in growth initiatives, including multi-cancer early detection (MCED) and minimal residual disease (MRD) testing. Beyond colorectal cancer, Exact Sciences is advancing a pipeline that targets the largest opportunities in oncology. Its MCED program (Cancerguard) aims to detect multiple cancer types from a single blood draw, with a pivotal study data readout expected in late 2026. Additionally, the company is developing MRD tests for recurrence monitoring in early-stage cancers, which could expand its total addressable market to over $50B. With a strong balance sheet and commercial infrastructure, Exact Sciences is well-positioned to capitalize on the shift toward early cancer detection and personalized medicine. However, competition from Guardant Health, Grail, and Freenome poses risks to its growth trajectory.

Upcoming Catalysts (preview)

• Q4 2026Multi-Cancer Early Detection (MCED) Pivotal Study Data Readout60% success
• Q3 2026Cologuard 2.0 Medicare National Coverage Determination (NCD) Expansion80% success
• Q1 2027FDA Approval or Clearance for Minimal Residual Disease (MRD) Test50% success